Compare AMZE & COCP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AMZE | COCP |
|---|---|---|
| Founded | 2019 | 2006 |
| Country | United States | United States |
| Employees | 4 | N/A |
| Industry | Beverages (Production/Distribution) | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.3M | 15.3M |
| IPO Year | N/A | 2011 |
| Metric | AMZE | COCP |
|---|---|---|
| Price | $0.38 | $1.04 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $3.00 | ★ $6.00 |
| AVG Volume (30 Days) | ★ 1.4M | 56.2K |
| Earning Date | 01-01-0001 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 8.02 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $12,712,091.00 |
| Revenue This Year | $6,741.66 | N/A |
| Revenue Next Year | $100.61 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.24 | $0.86 |
| 52 Week High | $11.76 | $2.19 |
| Indicator | AMZE | COCP |
|---|---|---|
| Relative Strength Index (RSI) | 47.35 | 55.36 |
| Support Level | $0.34 | $1.01 |
| Resistance Level | $0.42 | $1.10 |
| Average True Range (ATR) | 0.05 | 0.07 |
| MACD | -0.00 | 0.01 |
| Stochastic Oscillator | 61.93 | 89.54 |
Amaze Holdings Inc is a software company dedicated to empowering creators by providing comprehensive software solutions and services that facilitate e-commerce, social commerce, integrated commerce selling experiences, and the distribution of a premium wine brand. The group offers an end-to-end, creator-powered commerce platform offering tools for seamless product creation, modern e-commerce solutions, and scalable managed services.
Cocrystal Pharma Inc is a biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses. It employs structure-based technologies and Nobel Prize-winning expertise to create first and in-class antiviral drugs. It is developing CC-31244, an investigational, oral, broad-spectrum replication inhibitor called a non-nucleoside inhibitor (NNI).